|Bid||8.25 x 900|
|Ask||12.00 x 1100|
|Day's Range||9.72 - 10.05|
|52 Week Range||8.55 - 20.66|
|Beta (3Y Monthly)||4.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
REDWOOD CITY, Calif., Nov. 30, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the company has executed a 340B prime vendor program contract agreement.
Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
REDWOOD CITY, Calif., Nov. 27, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective November 14, 2018, the compensation committee of the company’s.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 8. Index (PMI) data, output in the Healthcare sector is rising.
Denny Lanfear became the CEO of Coherus BioSciences Inc (NASDAQ:CHRS) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
REDWOOD CITY, Calif., Nov. 12, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse.
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.
On a per-share basis, the Redwood City, California-based company said it had a loss of 87 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
REDWOOD CITY, Calif., Nov. 08, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
REDWOOD CITY, Calif., Oct. 22, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market.
REDWOOD CITY, Calif., Oct. 09, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018, the compensation committee of the company’s.
Why Are Wall Street Analysts Bullish on Mylan Stock? Mylan’s (MYL) Fulphila (pegfilgrastim), a biosimilar of Amgen’s (AMGN) Neulasta, received a positive CHMP (Committee for Medicinal Products for Human Use) opinion on September 21. Two other Neulasta biosimilars—Cinfa Biotech’s Pelmeg and Sandoz’s Ziextenzo—also received a positive CHMP opinion on September 21.
Amgen Inc. (AMGN) has not been affected by the decision of the European Commission to approve Coherus BioSciences' (CHRS) UDENYCA for commercialization in Europe. UDENYCA, one of the first pegfilgrastim products to gain the European marketing authorization, is a biosimilar of Amgen's Neulasta. Warning! GuruFocus has detected 1 Warning Sign with FB.
Coherus BioSciences, Inc. (CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim biosimilars to gain marketing authorization in Europe. "Today’s EC approval decision is the first marketing authorization for Coherus, an important step forward in realizing our mission of increasing access to biologic treatments to patients globally,” said Denny Lanfear, President and CEO of Coherus BioSciences.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $5.07 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.